Slide 1: The time for biosolutions is now
The time for biosolutions is now
Slide 2: Our products reach over half the world's population
H1 2026 | The time for biosolutions is now Our products reach over half the world’s population, with food biosolutions alone serving 2 billion people daily Biosolutions solve problems enabling… Detergents with fewer fossil-based chemicals remove stains and make Tasty, fermented Tastier, safer cold c
Slide 3: The biosolutions market is expanding
H1 2026 | The time for biosolutions is now The biosolutions market is expanding Addressing a ~60bn EUR biosolutions market Structural shifts driving increasing biosolutions readiness Illustrative Technology is ready to enable strong Specialty chemicals & biosolutions development ~1,000bn EUR ingredi
Slide 4: Fundamental growth drivers create strong pull for biosolutions
H1 2026 | The time for biosolutions is now Fundamental growth drivers create strong pull for biosolutions …driving higher demand for Clean label Sustainable agriculture Growing Reduced food waste Increasing Sustainable fuels Population energy needs Improved water and land use Alternative protein sou
Slide 5: Three strategic pillars deliver profitable growth through 2030
H1 2026 | The time for biosolutions is now Three strategic pillars deliver profitable growth through 2030 Grow Enhance the core our distinctive position Constantly advance distinctive Growth by focusing on the core business. By capabilities (Customer growing established industries and maturing Centr
Slide 6: Grow the core by robust building blocks
H1 2026 | The time for biosolutions is now Grow the core by robust building blocks We are doing well in the most attractive part of the Growth driven by our proven algorithm biosolutions market High New Our core Explorative playing field 2-3% growth opportunities 6-9% Upselling & adjacencies organic
Slide 7: Enhance and invest in our distinctive pillars
H1 2026 | The time for biosolutions is now Enhance and invest in our distinctive pillars Customer Innovation World-class centricity leadership scale • Strong regional commercial • Product superiority to • Resilient and expanding footprint and capability to co-create differentiate and increase value
Slide 8: Accelerate the biosolutions market by expanding and exploring
H1 2026 | The time for biosolutions is now Accelerate the biosolutions market by expanding and exploring Convert explorative growth opportunities into Expanding our technology platform to our core playing field further boost our core and make new Illustrative opportunities possible High Our core pla
Slide 9: Mastering the engineering of biology and fermentation
H1 2026 | The time for biosolutions is now Mastering the engineering of biology and fermentation Engineering strains… …which we scale up … before extracting the x200,000,000 through biosolution solving a fermentation… customer need Fungi, yeasts or bacteria Adding strain specific tailormade Enzymes,
Slide 10: Delivering a wide array of biosolutions
H1 2026 | The time for biosolutions is now Delivering a wide array of biosolutions Leveraging Enzymes Vitamins Polymers output from the Proteins Metabolites Biochemicals production- Sugars and Fuels Fats microorganism Fibers (HMO) Leveraging the Yeast Probiotics microorganism itself Food cultures Po
Slide 11: A stronger innovation platform equipped to unlock new opportunities
H1 2026 | The time for biosolutions is now A stronger innovation platform equipped to unlock new opportunities Leverage our …and cutting-edge … to deliver more value capabilities… technology platforms… to customers Assays & Translating needs Application Leverage existing and new innovations Customer
Slide 12: Prioritized and structured innovation drives high R&D return
H1 2026 | The time for biosolutions is now Prioritized and structured innovation drives high R&D return R&D allocation New product development Prioritization Prioritization Optimization Technology 10% +20% development 10% Screening of core and explorative early-stage innovation opportunities ~200 la
Slide 13: Strengthening position as leading global supplier of biosolutions
H1 2026 | The time for biosolutions is now Strengthening position as leading global supplier of biosolutions Unique position in biosolutions Strategic cornerstones to strengthen world-class scale Largest producer of biosolutions (enzymes, cultures, and probiotics) Produce current and novel biosoluti
Slide 14: There's a biosolution for (almost) everything
There's a biosolution for (almost) everything Commercial presence across +30 industies
Slide 15: Two divisions address Food & Health and Planetary Health needs
H1 2026 | There’s a biosolution for (almost) everything Two divisions address Food & Health and Planetary Health needs with highly attractive segments and stable end markets Food & Health Biosolutions Planetary Health Biosolutions 45% of total sales 55% of total sales Food & Beverages Human Health H
Slide 16: Food & Beverages | A stronger partner across end markets
H1 2026 | There’s a biosolution for (almost) everything | Food & Beverages Food & Beverages | A stronger partner across end markets Biosolutions toolbox Delivering on unmet needs Small cost in final product with high strategic value Consumer Customer Bacteria Yeast Strategic value e.g., quality, pro
Slide 17: Food & Beverages | Growth from strong footprint and broad toolbox
H1 2026 | There’s a biosolution for (almost) everything | Food & Beverages Food & Beverages | Growth from strong footprint and broad toolbox Market growth & pricing New • End market volumes expected to grow ~1-2% annually Explorative growth • Value-based pricing Upselling & adjacencies opportunities
Slide 18: Human Health | Foundation in place to unlock increasing potential
H1 2026 | There’s a biosolution for (almost) everything | Human Health Human Health | Foundation in place to unlock increasing potential Biosolutions Delivering on unmet needs Industry-leading capabilities, trustworthiness toolbox and unique microbiome insights Consumer & Consumer Customer customer
Slide 19: Human Health | Growth from strong core and attractive opportunities
H1 2026 | There’s a biosolution for (almost) everything | Human Health Human Health | Growth from strong core and attractive opportunities Market growth & pricing New • Drive above-market growth in probiotics through innovation and Explorative customization Upselling & growth • Continue scaling with
Slide 20: Household Care | Driving increased penetration of biosolutions
H1 2026 | There’s a biosolution for (almost) everything | Household Care Household Care | Driving increased penetration of biosolutions Biosolutions toolbox Delivering on unmet needs Small cost in final product with high strategic value Consumer Customer Strategic value e.g., quality, productivity,
Slide 21: Household Care | Growth from reformulation and emerging markets
H1 2026 | There’s a biosolution for (almost) everything | Household Care Household Care | Growth from reformulation and emerging markets Market growth & pricing New • End market volumes expected to grow ~1-2% annually Explorative growth • Value-based pricing Upselling & adjacencies opportunities App
Slide 22: Agriculture, Energy & Tech | Efficient biosolutions across end markets
H1 2026 | There’s a biosolution for (almost) everything | Agriculture, Energy & Tech Agriculture, Energy & Tech | Efficient biosolutions across end markets Biosolutions toolbox Delivering on unmet needs Small cost in final product with high strategic value Consumer Customer Strategic value e.g., qua
Slide 23: Agriculture, Energy & Tech | Growth from a well-diversified exposure
H1 2026 | There’s a biosolution for (almost) everything | Agriculture, Energy & Tech Agriculture, Energy & Tech | Growth from a well-diversified exposure and new opportunities Market growth & pricing New • End market volumes expected to grow ~1-2% annually Explorative • Value-based pricing Upselling
Slide 24: Financials
Financials hovonesis
Slide 25: Higher organic sales growth driven by volume, synergies and price
H1 2026 | Financials Higher organic sales growth driven by volume, synergies and price Organic sales growth Robust growth across industries & regions CAGR 6-9% 6-9% CAGR 8%2 6%1 CAGR Volume – grow from CAGR core Food & Human Household Agriculture, Beverages Health Care Energy & Tech Synergies – cros
Slide 26: Margin expansion from proven structural levers
H1 2026 | Financials Margin expansion from proven structural levers Adjusted EBITDA margin ~39% 37.1% Optimization Value and scale Cost Additional pricing inflation strategic 33.8% Productivity growth investments Investments to increase growth further, e.g., - Commercial presence - Adjacencies - Exp
Slide 27: Doubling ROIC while continuing to invest for higher growth
H1 2026 | Financials Doubling ROIC while continuing to invest for higher growth Securing capacity for higher growth Generating strong cash flow Increasing return on invested capital Accelerated growth Higher ~16% profitability 11.3% Asset utilization HSD* Expanding margin Amortization 10.1% profile
Slide 28: Staying true to capital allocation principles
H1 2026 | Financials Staying true to capital allocation principles Strong balance sheet 1 Invest for growth People, innovation and capacity Leverage ratio NIBD/EBITDA Could temporarily go higher if acquiring large 2 1.9x strategic assets Bolt-on acquisitions Complementary businesses and technologies
Slide 29: Sustainability is at the core of who we are and what we do
Sustainability is at the core of who we are and what we do
Slide 30: Driving sustainable development
H1 2026 | Sustainability Driving sustainable development +80% of our sales support the UN’s Sustainable Development Goals For example, biosolutions enable the world to: • Get more from raw materials • Reduce stress, boost immune • Save energy and water systems and improve gut health • Reduce the use
Slide 31: Sustainability agenda with clear targets and ambitions
H1 2026 | Sustainability Sustainability agenda with clear targets and ambitions Societal agenda Milestone targets (2025) Long-term targets and ambitions Reduce absolute GHG emissions from Scope 1 and 2 by 65% Reduce absolute GHG emissions from Scope 1 and 2 by 75% fand from scope 3 by 35% by 2030
Slide 32: Novonesis ownership and corporate structure
H1 2026 | Sustainability Novonesis ownership and corporate structure Novo Nordisk Foundation and Novo Holdings The Novo Group consists of three independent companies that are ultimately controlled by the Novo Nordisk Foundation: Novo Holdings, Novo Nordisk A/S and Novozymes A/S (Novonesis) Novo